Cargando…
Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent
Interleukin-12 (IL-12) has emerged as one of the most potent agents for anti-tumor immunotherapy. However, potentially lethal toxicity associated with systemic administration of IL-12 precludes its clinical application. Here we redesign the molecule in such a way that its anti-tumor efficacy is not...
Autores principales: | Wang, Pengju, Li, Xiaozhu, Wang, Jiwei, Gao, Dongling, Li, Yuenan, Li, Haoze, Chu, Yongchao, Zhang, Zhongxian, Liu, Hongtao, Jiang, Guozhong, Cheng, Zhenguo, Wang, Shengdian, Dong, Jianzeng, Feng, Baisui, Chard, Louisa S., Lemoine, Nicholas R., Wang, Yaohe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680234/ https://www.ncbi.nlm.nih.gov/pubmed/29123084 http://dx.doi.org/10.1038/s41467-017-01385-8 |
Ejemplares similares
-
Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent
por: Wang, Pengju, et al.
Publicado: (2018) -
A new oncolytic Vaccinia virus augments antitumor immune responses to prevent tumor recurrence and metastasis after surgery
por: Ahmed, Jahangir, et al.
Publicado: (2020) -
Treatment and Prevention of Lung Cancer Using a Virus-Infected Reprogrammed Somatic Cell-Derived Tumor Cell Vaccination (VIReST) Regime
por: Zhang, Zhe, et al.
Publicado: (2020) -
Syrian hamster as an ideal animal model for evaluation of cancer immunotherapy
por: Jia, Yangyang, et al.
Publicado: (2023) -
An effective therapeutic regime for treatment of glioma using oncolytic vaccinia virus expressing IL-21 in combination with immune checkpoint inhibition
por: Sun, Yijie, et al.
Publicado: (2022)